All
First Patient Dosed in Phase 3 Trial of IBI354 for Ovarian Cancer
The first patient was dosed in a phase 3 trial of IBI354 for platinum-resistant ovarian cancer with HER2 expression.
How Hope Erased My Fear of Testicular Cancer
Hope helped me navigate my testicular cancer diagnosis at 20, shaping my resilience and guiding my journey as a survivor.
Cretostimogene Has Durable Response in BCG-Unresponsive Bladder Cancer
Cretostimogene treatment shows best-in-class durability of response for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ
Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.
Colorectal Cancer Awareness: Key Signs, Screening and Prevention
Dr. Zachariah H. Foda discusses key colorectal cancer warning signs, the rise in younger diagnoses and more.
Unraveling Disparities and Genomic Advances Across Breast Cancer Care
Dr. Regina Hampton shares case studies from her own practice, illustrating how genomic insights have improved patient outcomes in those with breast cancer.
Reducing Bowel Complications Following Radiation in Prostate Cancer
SpaceOAR Hydrogel reduced the risk of bowel disorders, the need for colonoscopy and rectal resection following radiation therapy in prostate cancer.
First Patients Dosed in WU-CART-007 Trial for Blood Cancer Subtypes
The first patients have been dosed in a trial of CAR T therapy in relapsed/refractory T cell acute lymphoblastic leukemia or T cell lymphoblastic lymphoma.
Padcev With or Without Keytruda Elicits Responses in Urothelial Cancer
In metastatic urothelial carcinoma, Padcev plus Keytruda elicited responses in the first-line setting, with Padcev showing benefit in later lines.
First Patent Dosed With Pocenbrodib in Trial for Metastatic Prostate Cancer
First patient dosed in phase 1b/2a trial for castration-resistant metastatic prostate cancer, evaluating pocenbrodib alone and with other drug combinations.
Advancing ctDNA for Minimal Residual Disease Detection in Breast Cancer
Dr. Debu Tripathy explains how ctDNA is used to in breast cancer detection and how it can also indicate the presence of MRD.
Emphasizing the Importance of Breast Cancer Education and Screenings
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
The Unseen Long-Term Effects After Follicular Lymphoma Treatment
Life after treatment for follicular lymphoma brings long-term physical and emotional challenges, including immune system impacts and lasting social effects.
FDA Grants Fast Track Designation for Azer-Cel in Lymphoma Subset
FDA grants fast track designation to azer-cel, an allogeneic CAR T-cell therapy, for relapsed or refractory diffuse large B-cell lymphoma.
FDA Approves Gozellix for Advanced PSMA-PET Imaging in Prostate Cancer
The FDA has approved the use of Gozellix, a PSMA-PET imaging agent, to help detect prostate cancer using gallium-68 gozetotide in PSMA-PET scans.
Understanding NCCN Guidelines: Gavreto in First-Line RET Fusion NSCLC
Gavreto is recommended as a first-line treatment for metastatic RET fusion-positive, metastatic non-small cell lung cancer, with potential severe side effects.
Evolving Treatments and Advances in HER2-Positive Breast Cancer
Dr. Sara M. Tolaney discussed HER2-positive breast cancer, highlighting key trials, evolving treatment strategies, and the potential for improved outcomes.
The Power of Knowledge and Staying Informed in Breast Cancer Care
Dr. Debu Tripathy highlights the importance of staying informed on breast cancer advancements and how this empowers patients to make informed decisions.
What Patients With Breast Cancer Need to Know About Itovebi
Itovebi, approved for some patients with breast cancer, is the first PI3K inhibitor to display a survival benefit, according to Dr. Kevin Kalinsky.
A Heaven-Sent Sign About My Brother’s Lymphoma
Cancer runs in the family, and after I’d dealt with two breast cancers, my brother came down with lymphoma.
Golidocitinib Plus PD-1 Antibodies Being Explored in Lung Cancer Subset
Findings on golidocitinib for patients with non-small cell lung cancer whose disease has progressed on anti-PD-1 therapy will be presented this month.
Development of EO-3021 Discontinued for Gastric and GEJ Cancers
Elevation Oncology discontinues EO-3021 for gastric and gastroesophageal junction cancers after phase 1 trial shows insufficient efficacy.
Kadcyla Continues to Show Benefits in Early HER2+ Breast Cancer
In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.
Gene Expression Testing and Targeted Therapies in Breast Cancer Care
Gene expression testing helps determine chemotherapy needs for HR+ breast cancer, optimizing treatment and reducing unnecessary toxicity.
FDA Approves Keytruda in HER2+ Gastric, Gastroesophageal Junction Cancer
The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.
Painting an Accurate Portrait of Breast Cancer Survivorship
As a breast cancer survivor, I feel it is incumbent upon me to give an accurate picture of cancer to others, particularly newly diagnosed patients.
Fruzaqla Plus Sintilimab May Slow Renal Cell Carcinoma Progression
Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.
FDA Grants Compassionate Use Treatment to Namodenoson in Pancreatic Cancer
The FDA has granted approval to an act of compassionate use treatment with the anti-cancer drug Namodenoson for a patient with pancreatic cancer.
Disparities in Breast Cancer Care, Genomic Insights and Early Detection
Dr. Regina Hampton highlighted unmet needs in black women with breast cancer and details how genomic information can drive effective treatment options.
Darzalex Plus Revlimid Improves Outcomes in Newly Diagnosed Myeloma
Darzalex and Revlimid maintenance resulted in superior outcomes versus Revlimid alone following autologous stem cell transplantation in multiple myeloma.
